Filing Summary
Important identity discrepancy: The supplied filing is a Form 10-K for Zeta Acquisition Corp. III, not Kura Oncology, Inc. It covers the fiscal year ended December 31, 2014, and was filed February 27, 2015. The filing describes Zeta as a development-stage, blank-check and shell company.
Business Context and Reporting Period
Zeta was formed to identify and complete a business combination with an operating company. It had no active operating business, employees other than its management, material assets other than cash, or definitive acquisition agreement as of the filing date. Management stated that it intended to continue searching for a target without restricting the industry or geographic location.
The common stock was not publicly listed. There were 5,000,000 shares outstanding as of February 27, 2015, held by four record holders. The company had no revenue since inception on November 16, 2007.
Financial Condition and Results
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $(30,734) | $(28,611) |
| Net loss per share | $(0.01) | $(0.01) |
| Cash flow from operating activities | $(15,955) | $(23,234) |
| Cash flow from financing activities | $15,000 | $25,000 |
| Cash and cash equivalents at year-end | $5,613 | $6,568 |
| Total liabilities | $160,304 | $133,025 |
| Stockholders’ deficit | $(154,691) | $(123,957) |
FY 2014 operating expenses were $23,907, primarily for legal, accounting, audit, reporting and general administrative services. Interest expense was $6,827. The company had no gross profit or operating margin because it generated no revenue or operating cash flow.
Year-end assets were $5,613, consisting entirely of cash and cash equivalents. Liabilities included $125,000 of notes payable to stockholders, $24,002 of accrued interest, $8,900 of accrued expenses and $2,402 of accounts payable. The company had no investing cash flows.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $2,123, or approximately 7%, from $28,611 in 2013 to $30,734 in 2014.
- Operating cash use improved by $7,279, from $23,234 to $15,955.
- Cash decreased by $955 during 2014, compared with a $1,766 increase in 2013.
- Cash and cash equivalents declined by $955 year over year, while prepaid expenses declined from $2,500 to zero.
- Total liabilities increased by $27,279, principally reflecting an increase in stockholder notes from $110,000 to $125,000 and higher accrued interest.
- Stockholders’ deficit increased from $123,957 to $154,691 as a result of the 2014 net loss.
- Stockholders provided $15,000 of financing during 2014 through unsecured, 6% notes payable due on demand.
Guidance, Outlook, Risks and Unusual Items
Management expected to incur costs for SEC reporting and the investigation and completion of a potential acquisition. It expected to fund these costs through existing cash, deferred service-provider fees, and additional loans or investments from stockholders, management or other investors.
The filing states that the company’s ability to continue as a going concern depends on obtaining additional financing, generating future profitable operations, and identifying a suitable target for a potential reverse merger. Management provided no assurance that additional funding would be available or that a business combination would be completed.
- The company had only $5,613 of cash against $160,304 of liabilities at December 31, 2014.
- Stockholder notes were unsecured, bore interest at 6% and were due on demand, creating immediate liquidity pressure.
- The company had no revenues and was dependent on related parties for continued funding.
- A subsequent $15,000 stockholder advance was received after year-end; the note also bore interest at 6% and was due on demand.
- Any business combination could result in substantial dilution, loss of voting control by existing stockholders and replacement of the company’s directors.
- The company faced competition from other shell companies and acquisition vehicles with greater financial and operational resources.
- The auditor issued an unqualified opinion on the financial statements, but the statements were prepared on a going-concern basis and did not include adjustments that might be required if the company could not continue operating.
- Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation because the company qualified for an applicable exemption.
Most Important Facts to Verify
- Verify the issuer identity: the source document names Zeta Acquisition Corp. III, while the request metadata names Kura Oncology, Inc.
- Verify whether a business combination or reverse merger occurred after the February 27, 2015 filing date.
- Confirm the availability and terms of post-year-end financing and whether the demand notes were repaid, converted or remained outstanding.
- Review the company’s ability to meet obligations given $5,613 of cash and $160,304 of liabilities at year-end.
- Assess dilution, ownership and governance consequences of any future acquisition transaction.
- Confirm the absence of revenue-generating operations and the continuing going-concern uncertainty.